A type of infectious disorder, aspergillosis relates to an entire group of diseases that is connected with fungi known as the Aspergillus fumigatus. Our company is uniquely positioned to offer researchers and scientists engaged in any form of infectious disease research, such as aspergillosis, comprehensive and required services.
Overview of Aspergillosis
This fungal infection is mostly seen in individuals who are immunocompromised, such as people suffering from hematological tumors, organ transplant individuals, or those with advanced HIV/AIDS. Aspergillosis can manifest in different forms as invasive aspergillosis, chronic pulmonary aspergillosis, and allergic bronchopulmonary aspergillosis. Within the general population, the occurrence of infection of the invasive aspergillosis type is fairly low, running on an average of between 0.5 to 2 cases per 100,000 people each year.
Fig.1 Mechanisms of action of antifungal agents active against Aspergillus spp. (Zakaria, A., et al., 2020)
Pathogenesis of Aspergillosis
Environmental Aspergillus spore invasion of human lungs and sinus is prevalent, especially in individuals with a weakened immune system, this leads to the development of aspergillosis. In addition to those, this fungus has the capability of inducing an overreacting immune response in some individuals too, consequently resulting in the allergic forms of that specific disease.
Vaccine Development for Aspergillosis
NXT-2 Vaccine
A recombinant peptide vaccine, based on a conserved KEX1 sequence present on multiple pathogenic fungi.
VesiVax® Af3/9
VesiVax® adjuvant liposomes were chemically conjugated with two recombinant A. fumigatus surface antigens, Asp f3 and Asp f9.
Lam-CRM Conjugate
Laminarin (a carrier protein used in some glyco-conjugate bacterial vaccines) conjugated with the diphtheria toxoid CRM197.
Therapeutics Development for Aspergillosis
| Names |
Mechanism of Action |
Targets |
Research Phase |
| Voriconazole |
Inhibit cytochrome P450-dependent lanosterol 14α-demethylase |
CYP51A1 |
Approved |
| Lsavuconazole |
Lead to fungal cell membrane structure and function disorders |
CYP51A1 |
Approved |
| Caspofungin |
Glucan synthase inhibitor |
Glucan synthase |
Approved |
| Olorofim |
Inhibits the dihydroorotate dehydrogenase |
DHODH |
Phase IIb/III trials |
| Fosmanogepix |
Gwt1 enzyme inhibitor |
Gwt1 |
Phase II trials |
| Opelconazole |
An azole optimized for inhalation |
CYP51A1 |
Phase III trials |
| Rezafungin |
An echinocandin with long half-life time |
Glucan synthase |
Phase III trials |
| Ibrexafungerp |
A glucan synthase inhibitor |
Glucan synthase |
Phase III trials |
| Recombinant IFNγ |
Increases phagocytic antifungal activity |
/ |
Preclinical research |
| Adoptive T-cell transfer |
Enhance immune response |
/ |
Preclinical research |
| CAR T-cell therapy |
Secrete IFNγ upon activation by β-glucan, hence suppressing the growth of A. fumigatus |
/ |
Preclinical research |
Our Services
Our company has a very competent team that possesses a vast understanding of fungal pathogenesis alongside immunology and diagnostic development. We customize everything to the specific research requirements by using our diverse facilities which contain advanced technologies along with a large scale of platforms designed for the development of therapeutics, vaccines, and animal models against aspergillosis.
Vaccine Development Platforms
Therapeutic Development Platforms
Infectious Disease Models
To gain a broader insight into the complex pathogenesis of aspergillosis alongside developing efficient diagnostics and therapeutic schemes, our company provides various animal models of aspergillosis.
Aspergillus conidia (spores) are administered to immunocompromised animals that have been genetically engineered or administered chemicals (such as corticosteroids) to suppress their immune system.
Optional Models: Corticosteroid-induced model; Clec7atm1Gdb model, etc.
Fully equipped to offer customized solutions to suit your needs to expedite your research and further the global cause against difficult fungal infections. If you are interested in our service, we invite you to contact us to receive tailored quotes and further details regarding services.
Reference
- Zakaria, Ayate et al. "Recent trends in the epidemiology, diagnosis, treatment, and mechanisms of resistance in clinical Aspergillus species: A general review with a special focus on the Middle Eastern and North African region." Journal of infection and public health 13.1 (2020): 1-10.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
